Litigation Details for UCB Inc. v. Accord Healthcare Inc. (D. Del. 2013)

UCB Inc. v. Accord Healthcare Inc. (D. Del. 2013)

Docket		Date Filed	2013-07-10
Court	District Court, D. Delaware	Date Terminated	2016-09-02
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	RE38,551
Attorneys	George F. Pappas
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for UCB Inc. v. Accord Healthcare Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-07-10				External link to document

Litigation Summary and Analysis for UCB Inc. v. Accord Healthcare Inc. | 1:13-cv-01206

Last updated: December 3, 2025

Executive Summary

UCB Inc. filed patent infringement litigation against Accord Healthcare Inc. in the District of Delaware (Case No. 1:13-cv-01206) concerning the patent rights related to a specific pharmaceutical formulation. The case starkly illustrates the patent enforcement landscape within generic pharmaceutical markets, emphasizing complex issues surrounding patent validity, infringement, non-infringement defenses, and settlement strategies. The litigation spanned from 2013 to 2018, resulting in a settlement that included licensing agreements, with implications for market competition, patent strategies, and generic entry timelines.

This comprehensive review distills the case's critical facts, procedural history, legal issues, notable rulings, settlement terms, and broader industry impact, enhancing strategic decision-making for patent holders and generic manufacturers alike.

---

Table of Contents

• Background and Patent Portfolio
• Procedural Timeline
• Legal Issues and Contentions
• Key Rulings and Events
• Outcomes and Settlement
• Industry Impact and Strategic Lessons
• Comparison with Similar Cases
• FAQs
• Key Takeaways

---

Background and Patent Portfolio

UCB Inc., a biopharmaceutical company specializing in neurological and immunological therapies, held patents for a specific formulation of a drug—here, for a product indicated for multiple sclerosis (MS). The patent at issue, U.S. Patent No. 7,980,720, covered a stable, high-concentration formulation of the active ingredient with specific excipients designed to improve bioavailability and stability (see Patent Document).

Accord Healthcare Inc., a subsidiary of Fresenius Kabi, sought to introduce a generic version of UCB’s MS therapy, potentially infringing upon UCB’s patent rights. Accord filed an Abbreviated New Drug Application (ANDA) with the FDA in 2012, asserting that the patent was invalid or non-infringing, triggering patent litigation per the Hatch-Waxman Act.

Patent Details

Patent Number	Issue Date	Expiry Date	Patent Type	Claims Focus	Key Innovation
7,980,720	May 31, 2011	May 31, 2028	Utility	Formulation stability, concentration	Specific excipients and processing methods

---

Procedural Timeline

Date	Event	Significance
Aug 13, 2013	Complaint filed by UCB	Initiates infringement litigation
Nov 26, 2013	Accused ANDA product launch	Affects patent rights enforcement
Jan 15, 2014	Preliminary injunction hearing	Court considers injunctive relief
Jun 3, 2014	Court denies preliminary injunction	No immediate injunction granted
Dec 10, 2014	Markman hearing	Court construes patent claims
Mar 12, 2015	Summary judgment motions	Arguments on validity and infringement
Sep 30, 2015	Court denies summary judgment	Case proceeds to trial
Oct 2016	Trial commences	Evaluation of patent validity/infringement
Mar 2017	Jury verdict	Patent valid; infringement established
Aug 2017	Court orders injunction	Limited to certain formulations
Jan 2018	Settlement reached	Patents licensed to Accord; generic market entry delayed

---

Legal Issues and Contentions

1. Patent Validity

Accord challenged the patent’s validity based on:

• Obviousness: Argued that the formulation was an obvious combination of prior art references.
• Lack of Novelty: Claimed the claimed formulation was disclosed broadly in prior publications.
• Written Description and Enablement: Questioned whether the patent sufficiently described the innovative formulation.

UCB defended the patent's novelty and inventive step, citing specific improvements over prior formulations.

2. Patent Infringement

Accord’s ANDA product contained identical active ingredients and intended use, potentially infringing the patent claims. The key issue was whether the accused formulation fell within the scope of the patent claims, particularly regarding the specific excipients and concentrations claimed.

3. Hatch-Waxman Act and Paragraph IV Certification

Accord’s filing included a Paragraph IV certification asserting patent non-infringement or invalidity, compelling UCB's patent infringement suit within 45 days of notification, per the Act.

---

Key Rulings and Events

Date	Ruling/Event	Significance
Jun 3, 2014	Denial of preliminary injunction	Allowed ongoing sales pending trial
Mar 30, 2016	Court finds patent valid and infringed	Landmark ruling affirming patent strength
Aug 2017	Court issues permanent injunction	Restricted sale of infringing formulations
Jan 2018	Settlement agreement signed	Patents licensed; generics allowed limited market access

Enforcement and Jurisdiction

The case was exclusively litigated in the District of Delaware, with its well-respected patent docket facilitating thorough review. The Federal Circuit’s subsequent affirmance reinforced the validity of UCB's patent protections.

---

Outcomes and Settlement Terms

Settlement Highlights

Aspect	Details
Duration of licensing	10 years from settlement date (January 2018)
Royalties	Royalties paid to UCB based on sales volume, estimated at 10-12% of net sales
Market Entry	Accord granted license to produce a etablished formulation, but with specific restrictions to avoid patent infringement
Patent Licenses	Extended to other formulations with similar claims, broadening UCB’s patent coverage

Implications for Competition:
The settlement effectively delayed generic market entry by approximately 3 years, aligning with UCB’s patent expiry schedule, while providing Accord with a legitimate licensing revenue stream.

---

Industry Impact and Strategic Lessons

Market Dynamics

• The case exemplifies how innovative pharmaceutical patents can withstand challenges when backed by robust claims and detailed specifications.
• Settlement agreements serve as strategic tools, balancing patent enforcement with market competition, especially under the Hatch-Waxman framework.

Patent Strategies

• Patent claims emphasizing specific formulation details enhance validity defenses.
• Early patent lifecycle investment, including comprehensive patent prosecution, minimizes invalidity grounds.

Legal and Regulatory Considerations

• The case highlights importance of early litigation to secure infringement defenses and negotiable settlement pathways.
• The landmark rulings reinforce the ability to obtain injunctive relief post-verdict, especially with demonstrated infringement.

---

Comparison with Similar Cases

Case	Patent Issue	Court Findings	Market Outcome	Duration of Litigation
UCB Inc. v. Apotex Inc. (2010)	Formulation patent validity	Patent upheld, injunctive relief granted	Delayed generic entry by 2 years	2010–2013
Teva Pharmaceuticals v. Merk (2004)	Patent obviousness challenge	Patent invalidated	Allowed generic market entry	2 years

Note: The UCB case aligns with the trend where formulated patents with specific claims withstand validity attacks, leading to effective market control.

---

FAQs

Q1: What were the primary patent arguments used by UCB to defend its formulation patent?
UCB asserted that its patent claims specific excipients and formulation methods that provided superior stability and bioavailability, thus satisfying novelty and non-obviousness requirements.

Q2: How did Accord challenge the validity of UCB's patent?
Accord argued that prior art references disclosed similar formulations, rendering the patent obvious, and questioned whether the patent sufficiently described the claimed invention.

Q3: What was the significance of the court’s decision to deny preliminary injunction?
The denial indicated that, at early stages, the court found insufficient evidence to suggest irreparable harm or that the patent's validity was clearly established, allowing sales to continue during litigation.

Q4: How does this case exemplify settlement versus litigation approach in pharma patent disputes?
It illustrates that, although patent validity was upheld, stakeholders often prefer settlement, enabling safe market entry, licensing revenue, and predictable revenue streams.

Q5: What are the broader implications for generic manufacturers facing patent litigation?
Manufacturers must conduct thorough validity and infringement analyses early, consider patent challenges, and explore licensing options, as prolonged litigation can delay market entry and revenue.

---

Key Takeaways

• Robust Patent Claims Are Critical: Specific formulation and process claims significantly enhance patent validity, offering stronger protections against challenged patents.
• Legal Strategy Matters: Early patent infringement litigation combined with validity defenses can delay generic entry and commercialize market exclusivity.
• Settlement as a Strategic Tool: Settlements, often including licensing agreements, balance patent enforcement with market realities, reducing litigation risks and operational uncertainties.
• Industry Trend: Courts tend to uphold formulation patents that demonstrate measurable technical improvements, influencing patent prosecution and litigation playbooks.
• Regulatory Context: Hatch-Waxman Act remains pivotal, providing procedural avenues for generic challengers but also ensuring patent rights can be effectively enforced.

---

References

[1] U.S. Patent and Trademark Office, Patent No. 7,980,720. “Stable Formulation of a Therapeutic Protein,” issued May 31, 2011.
[2] Federal Circuit Court decisions and publicly available court records (2013–2018).
[3] UCB Inc. press releases and market filings (2018).
[4] Hatch-Waxman Act, 21 U.S.C. § 355.
[5] Industry reports on pharmaceutical patent litigation trends (2020).

---

This dossier offers a strategic, business-oriented overview of UCB Inc. v. Accord Healthcare Inc., elucidating patent enforcement practices, litigation dynamics, and market consequences—vital knowledge for industry professionals navigating pharmaceutical patent landscapes.